97069 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Blood coagulation or fibrinolysis factors Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
Platelet targeted treatment
#302Factor VIII proteins having ancestral sequences, expression vectors, and uses related thereto
#303Modulation of antigen immunogenicity by deleting epitopes recognized by NKT cells
#304Optimised coding sequence and promoter
#305Compositions and methods for enhancing coagulation factor VIII function
#306Oligopeptide-free cell culture media
#307FACTOR VIII WITH EXTENDED HALF-LIFE AND REDUCED LIGAND-BINDING PROPERTIES
#308Methods and compositions relating to improved lentiviral vectors and their applications
#309VIRAL INACTIVATION USING IMPROVED SOLVENT-DETERGENT METHOD
#310Recombinant promoters and vectors for protein expression in liver and use thereof
#311Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor
#312Process For Isolation of Plasma or Serum Proteins
#313Factor VIII polypeptide formulations
#314FACTOR VIII GLYCOFORMS
#315Systems for Factor VIII Processing and Methods Thereof
#316FVIII PEPTIDES FOR IMMUNE TOLERANCE INDUCTION AND IMMUNODIAGNOSTICS
#317Immunoglobulin chimeric monomer-dimer hybrids
#318Nucleophilic catalysts for oxime linkage
#319Expression cassette for packaging and expression of variant factor VIII for the treatment of hemostasis disorders
#320Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A
#321Immunoglobulin chimeric monomer-dimer hybrids
#322Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A
#323Method for identifying epitope on protein
#324PURIFICATION OF BIOLOGICAL PRODUCTS BY CONSTRAINED COHYDRATION CHROMATOGRAPHY
#325CpG reduced factor VIII variants, compositions and methods and uses for treatment of hemostasis disorders
#326Method for improved isolation of recombinantly produced proteins
#327Biologically active peptides
#328Albumin-purification method comprising a nanofiltration step, solution, and composition for therapeutic use containing the same
#329Serum-free stable transfection and production of recombinant human proteins in human cell lines
#330Modified von Willebrand Factor
#331Polypeptide substrate for the detection of von Williebrand factor cleaving protease ADAMTS13
#332METHOD FOR REDUCING THE IMMUNE RESPONSE TO A BIOLOGICALLY ACTIVE PROTEIN
#333Production of recombinant von Willebrand factor in a bioreactor
#334Liver-specific constructs, factor VIII expression cassettes and methods of use thereof
#335Lentiviral vectors
#336Adeno-associated virus factor VIII vectors
#337Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor
#338Adeno-associated virus factor VIII vectors, associated viral particles and therapeutic formulations comprising the same
#339Factor VIII chimeric proteins and uses thereof
#340Factor VIII variants having a decreased cellular uptake
#341INTEGRATED CONTINUOUS BIOMANUFACTURING PROCESS
#342Targeted coagulation factors and method of using the same
#343FACTOR VIII B CELL EPITOPE VARIANTS HAVING REDUCED IMMUNOGENICITY
#344Methods of delivering factor VIII encoding nucleic acid sequences
#345Chimeric clotting factors
#346MEDIUM SUPPLEMENTS FOR IMPROVED PROCESS PERFORMANCE
#347Factor VIII Molecules with Reduced VWF Binding
#348Factor VIII Fusion Protein
#349Method of producing recombinant high molecular weight vWF in cell culture
#350MEDIUM FOR THE PROTEIN-FREE AND SERUM-FREE CULTIVATION OF CELLS
#351FACTOR VIII COMPOSITIONS AND METHODS OF MAKING AND USING SAME
#352Methods and compositions relating to improved lentiviral vectors and their applications
#353Medium for the protein-free and serum-free cultivation of cells
#354Method for improving the stability of purified factor VIII after reconstitution
#355Blood coagulation protein conjugates
#356Recombinant factor VIII proteins
#357Process for producing and purifying factor VIII and its derivatives
#358On-column viral inactivation methods
#359USE OF CATION-EXCHANGE CHROMATOGRAPHY IN THE FLOW-THROUGH MODE TO ENRICH POST-TRANSLATIONAL MODIFICATIONS
#360Methods for testing anti-thrombotic agents
#361Process for manufacturing factor VIII having an improved ratio of FVIII:C/FVIII/AG
#362Compounds Suitable for Treatment of Haemophilia
#363RECOMBINANT FACTOR VIII PROTEINS
#364Population pharmacokinetics tools and uses thereof
#365Compositions and methods for suppression of inhibitor formation against coagulation factors in hemophilia patients
#366Method to concentrate von willebrand factor or complexes thereof
#367Stabilized Factor VIII Variants
#368Stabilizing agent for pharmaceutical proteins
#369Targeted Delivery of Factor VIII Proteins to Platelets
#370THROMBIN CLEAVABLE LINKER WITH XTEN AND ITS USES THEREOF
#371CELL CULTURE PROCESSES
#372Optimized human clotting factor VIII gene expression cassettes and their use
#373THROMBIN CLEAVABLE LINKER
#374Conjugated Factor VIII Molecules
#375METHODS AND COMPOSITIONS RELATED TO LARGE SCALE PRODUCTION OF PROTEINS
#376Compounds Suitable for Treatment of Haemophilia
#377Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor
#378FACTOR VIII: REMODELING AND GLYCOCONJUGATION OF FACTOR VIII
#379Covalent complex of von Willebrand Factor and factor VIII, compositions, and uses relating thereto
#380Factor VIII zwitterionic polymer conjugates
#381Factor VIII-XTEN fusions and uses thereof
#382Purification of chimeric FVIII molecules
#383Serum-free stable transfection and production of recombinant human proteins in human cell lines
#384ANTI-FACTOR VIII ANTIBODIES OR USES THEREOF
#385Modified Glycoproteins Having Circulating Half-Lives
#386Pharmaceutical Composition Suitable for Treatment of Haemophilia
#387Anti-GPIIB/IIIA antibodies or uses thereof
#388Method for treating bleeding disorders
#389MUTANT FACTOR VIII COMPOSITIONS AND METHODS
#390Oligopeptide-free cell culture media
#391INDUCTION OF ANTIGEN-SPECIFIC TOLERANCE
#392Methods and Compositions for Treating Bleeding Disorders
#393Biologically active peptides
#394Variant factor VIII polypeptides and methods of their production and use
#395TARGETED ELIMINATION OF FACTOR VIII IMMUNE CELLS
#396Purification of VWF
#397Process for isolation of plasma or serum proteins
#398FORMULATIONS AND METHODS FOR INCREASED RECOMBINANT PROTEIN PRODUCTION
#399FACTOR VIII VARIANTS HAVING A DECREASED CELLULAR UPTAKE
#400Factor VIII Molecules With Reduced VWF Binding
#401Hydrophobic charge induction chromatographic depletion of a protein from a solution
#402Optimized factor VIII gene
#403METHODS FOR ISOLATING BLOOD PRODUCTS FROM AN INTER-ALPHA INHIBITOR PROTEIN-DEPLETED BLOOD PRODUCT MATERIAL
#404Medium Supplements for Improved Process Performance
#405Variant of antihemophilic factor VIII having increased specific activity
#406Platelet targeted treatment
#407Double Mutant Coagulation Factor VIII and Methods Thereof
#408Protein stabilizing factors
#409MONOLITH-BASED PSEUDO-BIOAFFINITY PURIFICATION METHODS FOR FACTOR VIII AND APPLICATIONS THEREOF
#410Factor VIII mutation repair and tolerance induction
#411Muteins of clotting factor VIII
#412MODIFIED FVIII APITOPE PEPTIDES
#413Protein expression enhancing polypeptides
#414Optimised coding sequence and promoter
#415Methods of Using FVIII Polypeptide
#416Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
#417Methods for producing recombinant factor VIII chains from non-filamentous fungi, their functional reconstitution and applications thereof
#418FVIII peptides for immune tolerance induction and immunodiagnostics
#419Compositions and Methods of Treatment of Black Hemophiliac Patients
#420Compositions and Methods of Treatment of Black Hemophiliac Patients
#421Cell line expressing single chain factor VIII polypeptides and uses thereof
#422Methods for use of mixed multifunctional surfaces for reducing aggregate content in protein preparations
#423Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor
#424Nucleic acid molecules encoding modified factor VIII proteins
#425Factor VIII compositions and methods of making and using same
#426Compositions, methods and uses
#427Method of purifying therapeutic proteins
#428Albumin-purification method comprising a nanofiltration step, solution, and composition for therapeutic use containing the same
#429Polypeptide substrate for the detection of von williebrand factor cleaving protease ADAMTS13
#430Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor
#431Coagulation factor VIII with reduced immunogenicity
#432Compounds Suitable for Treatment of Haemophilia
#433Adeno-associated virus factor VIII vectors
#434METHOD OF PRODUCING RECOMBINANT HIGH MOLECULAR WEIGHT vWF IN CELL CULTURE
#435Compositions and methods for enhancing coagulation factor VIII function
#436Pharmaceutical Composition Suitable for Treatment of Haemophilia
#437Serum-free stable transfection and production of recombinant human proteins in human cell lines
#438Biologically active peptides
#439FACTOR VIII COMPOSITIONS AND METHODS OF MAKING AND USING SAME
#440Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
#441RECOMBINANT FACTOR VIII HAVING ENHANCED STABILITY FOLLOWING MUTATION AT THE A1-C2 DOMAIN INTERFACE
#442Chimeric factor VIII polypeptides and uses thereof
#443Method of producing recombinant high molecular weight vWF in cell culture
#444Efficient production of peptides
#445Recombinant expression vector system for variants of coagulation factor VIII and von Willebrand factor
#446Alpha-1 antitrypsin variant, preparation method thereof and use thereof
#447Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy
#448METHOD OF PRODUCING FACTOR VIII PROTEINS BY RECOMBINANT METHODS
#449Von willebrand factor variants having improved factor VIII binding affinity
#450Composition exhibiting a von Willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
#451VARIANT SERUM ALBUMIN WITH IMPROVED HALF-LIFE AND OTHER PROPERTIES
#452METHOD FOR PRODUCTION OF FACTOR VIII
#453Factor VIII polypeptide formulations
#454METHOD FOR REDUCING THE IMMUNE RESPONSE TO A BIOLOGICALLY ACTIVE PROTEIN
#455Factor VIII chimeric and hybrid polypeptides, and methods of use thereof
#456MODIFIED COAGULATION FACTORS WITH PROLONGED IN VIVO HALF-LIFE
#457Method for improving the stability of purified factor VIII after reconstitution
#458Conjugated factor VIII molecules
#459Purification of biological products by constrained cohydration chromatography
#460Targeted coagulation factors and method of using the same
#461Binding molecules for human factor VIII and factor VIII-like proteins
#462Stabilizing agent for pharmaceutical proteins
#463METHODS FOR ISOLATING BLOOD PRODUCTS FROM AN INTER-ALPHA INHIBITOR PROTEIN-DEPLETED BLOOD PRODUCT MATERIAL
#464Modified factor VIII and factor IX genes
#465Recombinant factor VIII having enhanced stability following mutation at the A1-C2 domain interface
#466METHODS AND SYSTEMS FOR OPTIMIZING PERFUSION CELL CULTURE SYSTEM
#467Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life
#468Factor VIII variants having a decreased cellular uptake
#469METHOD FOR THE PRODUCTION OF RECOMBINANT HUMAN FACTOR VIII
#470Method of increasing the productivity of eucaryotic cells in the production of recombinant FVIII
#471Large scale and stable production of human FVIII in the human cell line Sk-Hep-1
#472Compounds suitable for treatment of haemophilia
#473Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor
#474AQUEOUS FACTOR VIII SOLUTION
#475Devices and methods for integrated continuous manufacturing of biological molecules
#476Transgene delivering retrovirus targeting collagen exposed at site of tissue injury
#477Variant of antihemophilic factor VIII having increased specific activity
#478Systems for factor VIII processing and methods thereof
#479Modulation of antigen immunogenicity by deleting epitopes recognized by NKT cells
#480Factor VIII conjugates
#481Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof
#482Compositions containing factor VIII glycoforms
#483Process for protein production
#484Processable single chain molecules and polypeptides made using same
#485Polymer von Willebrand factor-conjugates
#486Methods for modeling protein stability
#487Heterodimeric human IgG1 polypeptides with isoelectric point modifications
#488CONJUGATED BLOOD COAGULATION FACTOR VIII
#489Factor VIII glycoforms
#490Factor VIII T Cell Epitope Variants Having Reduced Immunogenicity
#491NEW STABILIZING AGENT FOR PHARMACEUTICAL PROTEINS
#492Factor VIII B Cell Epitope Variants Having Reduced Immunogenicity
#493Methods and compositions relating to improved lentiviral vectors and their applications
#494Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof
#495Recombinant factor VIII having increased stability
#496Compounds and Methods for FRET Based Measurement of Enzyme Activity
#497INACTIVATION RESISTANT FACTOR VIII
#498Selective modification of proteins
#499Factor VIII fusion protein
#500Factor VIII Molecules With Reduced VWF Binding
#501Systems and methods to increase protein yield from recombinant manufacturing processes
#502Optimised coding sequence and promoter
#503Fluorogenic substrate for ADAMTS13
#504Factor VIII Compositions and Methods of Making and Using Same
#505Von willebrand factor- and factor VIII-polymer conjugates having a releasable linkage
#506Modified factor VIII
#507Conjugated proteins
#508Modified factor VIII and factor IX genes and vectors for gene therapy
#509Recombinant protein production in heterologous systems
#510Conjugated FVIII variants
#511MODIFIED RECOMBINANT FACTOR VIII AND VON WILLEBRAND FACTOR AND METHODS OF USE
#512Compositions and methods for enhancing coagulation Factor VIII function
#513von Willebrand factor (vWF)-containing preparations, and methods, kits, and uses related thereto
#514Isolated nucleic acids encoding activated factor V and methods for production thereof
#515Transgene delivering retrovirus targeting collagen exposed at site of tissue injury
#516Nucleic acid and amino acid sequences encoding high-level expressor factor VIII polypeptides and methods of use
#517OPTIMIZED MESSENGER RNA
#518Method for producing proteins in that lack detectable cross binding activity to antibodies against host cell antigens
#519Viral Inactivation Using Improved Solvent-Detergent Method
#520Inactivation Resistant Factor VIII
#521Purification of factor VIII using a conductivity gradient
#522FACTOR VIII COMPOSITIONS AND METHODS OF MAKING AND USING SAME
#523High yield suspension cell line, system, and method for making same
#524ALBUMIN FUSED COAGULATION FACTORS FOR NON-INTRAVENOUS ADMINISTRATION IN THE THERAPY AND PROPHYLACTIC TREATMENT OF BLEEDING DISORDERS
#525Von Willebrand factor- and factor VIII-polymer conjugates having a releasable linkage
#526Factor VIII Variants and Methods of Use
#527Polymer-von Willebrand factor-conjugates
#528FVIII peptides for immune tolerance induction and immunodiagnostics
#529Modified factor VIII peptides
#530TARGETED DELIVERY OF FACTOR VIII PROTEINS TO PLATELETS
#531Transgenic non-human animals expressing human blood clotting factors and uses thereof
#532Procoagulant peptides
#533Recombinant factor VIII having enhanced stability following mutation at the A1-C2 domain interface
#534Binding molecules for human factor VIII and factor VIII-like proteins
#535Novel Glycosylated Polypeptides
#536Nucleophilic catalysts for oxime linkage
#537Method of producing recombinant high molecular weight vWF in cell culture
#538Method of producing recombinant ADAMTS13 in cell culture
#539METHOD OF PRODUCING FACTOR VIII PROTEINS BY RECOMBINANT METHODS
#540Method for the Treatment of Hemophilia
#541Recombinant FcRn and Variants Thereof for Purification of Fc-Containing Fusion Proteins
#542Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
#543Modification of Factor VIII
#544Medium for the protein-free and serum-free cultivation of cells
#545Process for highly selective purification of two plasma proteins: von willebrand factor (vWF) and fibronectin (Fn)
#546PROCESS FOR OBTAINING A CONCENTRATE OF VON WILLEBRAND FACTOR OF A COMPLEX OF FACTOR VIII/VON WILLEBRAND FACTOR AND USE OF THE SAME
#547Recombinantly produced human factor VIII and IX
#548Recombinant platelet collagen receptor glycoprotein VI and its pharmaceutical use
#549PROTEOLYTICALLY CLEAVABLE FUSION PROTEINS WITH HIGH MOLAR SPECIFIC ACTIVITY
#550Factor VIII, von willebrand factor or complexes thereof with prolonged in vivo half-life
#551Immunoglobulin chimeric monomer-dimer hybrids
#552Process of purifying coagulation factor VIII
#553Methods for Chemically Synthesizing Immunoglobulin Chimeric Proteins
#554OLIGOPEPTIDE-FREE CELL CULTURE MEDIA
#555Methods of reducing hemorrhage due to surgical procedure
#556Modified Blood Clotting Factors And Methods Of Use
#557Modified Coagulation Factor VIII With Enhanced Stability and Its Derivatives
#558Factor VIII polypeptide having factor VIII:C activity
#559Efficient production of peptides
#560Factor VIII polymer conjugates
#561Factor VIII polymer conjugates
#562Factor VIII Muteins with Reduced Immonugenicity
#563Polymer-von Willebrand factor-conjugates
#564Purification of VWF for increased removal of non-lipid enveloped viruses
#565Nucleic acid and amino acid sequences encoding high-level expressor factor VIII polypeptides and methods of use
#566Targeted Coagulation Factors and Method of Using the Same
#567Transgene delivering retrovirus targeting collagen exposed at site of tissue injury
#568OSTEOARTHRITIS-SENSITIVE GENE
#569Method of Producing Factor VIII Proteins by Recombinant Methods
#570TRANSGENIC PROTEINS FROM MULTI-GENE SYSTEMS, METHODS, COMPOSITIONS, USES AND THE LIKE RELATING THERETO
#571STRATEGIES TO PREVENT AND/OR TREAT IMMUNIE RESPONSES TO SOLUBLE ALLOFACTORS
#572FVIII peptides and their use in tolerising haemophiliacs
#573VIII factors for the treatment of type A hemophilia
#574METHOD FOR PURIFYING FACTOR VIII AND VON WILLEBRAND FACTOR
#575Purification of factor XIII polypeptides from biological materials
#576Methods and compositions for purifying human factor VIII, factor VIII-like proteins or fragments thereof
#577GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES
#578Modified factor VIII and factor IX genes and vectors for gene therapy
#579Compositions, methods and uses
#580Factor VIII: remodeling and glycoconjugation of factor VIII
#581Allelic Variants of Human Factor VIII
#582Purification of factor VIII using a mixed-mode or multimodal resin
#583Demannosylated recombinant factor VIII for the treatment of patients with haemophilia A
#584Use of a chromatography substrate for reducing the amount of ADAMTS13 in a solution derived from plasma
#585Serum-free stable transfection and production of recombinant human proteins in human cell lines
#586Recombinant expression vector system for variants of coagulation factor VIII and von willebrand factor
#587Eukaryotic layered vector initiation systems
#588Recombinant human blood coagulation factor VIII protein, composition, use of a recombinant factor VIII protein, use of a composition, method of obtaining a recombinant human blood coagulation factor VIII protein and use thereof
#589Pegylated factor VIII
#590FACTOR VIII COMPOSITIONS AND METHODS
#591Modified coagulation factors with prolonged in vivo half-life
#592SUBSTANCE WITH ANTITHROMBOTIC ACTIVITY AND METHOD FOR DETECTING GLYCOKALLIDIN
#593Factor VIII polypeptide titers in cell cultures
#594Factor VIII polymer conjugates
#595Factor VIII polymer conjugates
#596Process for producing and purifying factor VIII and its derivatives
#597Method Of Complexing A Protein By The Use Of A Dispersed System And Proteins Thereof
#598MINIMIZED SMALL PEPTIDES WITH HIGH AFFINITY FOR FACTOR VIII AND FACTOR VIII-LIKE PROTEINS
#599Factor VIII conjugates
#600OPTIMIZED MESSENGER RNA